NanoViricides Inc. (NNVC)

[Duster]

PR Newswire and BusinessWire News
NanoViricides Inc NNVC:OTC Bulletin Board Market
NanoViricides Announces Dramatic Viral Load Reduction in Lethal In Vivo Influenza Study
BusinessWire
7:00 AM ET
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reports that its optimized FluCide(TM) drug candidates achieved dramatic reduction in viral load within the lungs of animals infected with a lethal dose of H1N1 influenza virus.

The Company has previously announced that these optimized FluCide drug candidates demonstrated dramatically improved survival in this animal study. We now report that there was good correlation between viral load reduction and the length of survival.

The most effective FluCide candidate demonstrated a fif teen-fold (15X) greater viral load reduction as compared to Tamiflu(r) (Roche), and a thirty-fold (30X) greater viral load reduction as compared to untreated animals. Tamiflu demonstrated a viral load reduction of only twofold (2X) compared to the untreated animals in this high infection, lethality study. The viral load is a measure of the amount of infectious influenza virus in the lungs of infected animals. This profound decrease in viral load is consistent with the observed substantial increase in length of survival upon nanoviricide treatment. The Company previously reported that animals treated with this FluCide candidate survived for as long as 18.1 days on average, compared with only 7.8 days for Tamiflu treated animals. A survival length of 21 days would be considered indefinite survival in this animal model.

The studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS, at KARD Scientific, MA. One million virus particles of Influenza A Strain A/WS/33 (H1N1) were aspirated directly into the lungs of mice. A repeat infection was performed at 22 hrs. This influenza model was designed to be uniformly fatal in 100% of the infected, untreated animals within 5 days after infection. Treatment with both FluCide candidates and Tamiflu commenced 24 hours after the initial viral infection. Tamiflu was administered orally twice daily at 20mg/kg (i.e. 40mg/kg/day) while the nanoviricides were intravenous injections at 100mg/kg every 48 hrs.

"Treatment with the Nanoviricide compounds resulted in a profound reduction in viral load. Other overt parameters of virus infection were similarly decreased. In addition, survival time was significantly increased," said Krishna Menon, PhD, President of KARD Scientific.

The nanoviricides have been well tolerated with no overt adverse effects observed even in animals treated for more than 2 weeks. The Company, therefore, believes that dosage of the nanoviricides can be further increased to achieve greater levels of effectiveness. Additional data related to various parameters including histology and cytokines are pending from this study. The Company plans to report on the same as the datasets are analyzed.

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes kera titis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors whi ch are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, th ey may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

SOURCE: NanoViricides, Inc.

NanoViricides, Inc. Amanda Schuon, 310-550-7200 [e-mail]


Business Wire is a registered trademark of Business Wire. PR Newswire is a registered trademark of PR Newswire Association, Inc.

http://finance.yahoo.com/news/NanoViricides-Announces-bw-434013559.html?x=0&.v=1